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Abstract
Devil facial tumour disease (DFTD) comprises two genetically distinct transmissible cancers (DFT1 and DFT2) endanger-
ing the survival of the Tasmanian devil (Sarcophilus harrisii) in the wild. DFT1 first arose from a cell of the Schwann cell 
lineage; however, the tissue-of-origin of the recently discovered DFT2 cancer is unknown. In this study, we compared the 
transcriptome and proteome of DFT2 tumours to DFT1 and normal Tasmanian devil tissues to determine the tissue-of-origin 
of the DFT2 cancer. Our findings demonstrate that DFT2 expresses a range of Schwann cell markers and exhibits expression 
patterns consistent with a similar origin to the DFT1 cancer. Furthermore, DFT2 cells express genes associated with the 
repair response to peripheral nerve damage. These findings suggest that devils may be predisposed to transmissible cancers 
of Schwann cell origin. The combined effect of factors such as frequent nerve damage from biting, Schwann cell plasticity 
and low genetic diversity may allow these cancers to develop on rare occasions. The emergence of two independent transmis-
sible cancers from the same tissue in the Tasmanian devil presents an unprecedented opportunity to gain insight into cancer 
development, evolution and immune evasion in mammalian species.
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Introduction
The mammalian immune system has been shaped over 
millions of years to protect against infectious disease 
and external threats to physiological homeostasis. In 
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mammals, naturally occurring transmissible cancers have 
only been identified in two species: canine transmissible 
venereal tumour in dogs (Canis lupus familiaris) [1] and 
devil facial tumour disease (DFTD) in Tasmanian devils 
(Sarcophilus harrisii) [2]. The recent emergence of two 
genetically independent transmissible cancers (DFT1 and 
DFT2) in the Tasmanian devil has highlighted a poten-
tial predisposition of this marsupial species to developing 
contagious cancers [3, 4]. Known collectively as DFTD, 
both DFT1 and DFT2 cancers manifest as aggressive 
facial tumours that are transferred between hosts as allo-
geneic grafts during typical biting behaviours of the Tas-
manian devil [2, 3]. Although DFT1 and DFT2 are almost 
indistinguishable by gross examination and share similar 
patterns of mutation [4], karyotypic and genetic studies 
have revealed the independent nature of these two can-
cers. Specifically, complex chromosomal rearrangements 
and microsatellite genotypes that are identical within 
each clonal lineage differ between DFT1 and DFT2 [3, 
5]. Karyotypic and genetic studies have also revealed two 
homologous copies of the X chromosome in DFT1 cells 
and an X and Y in DFT2, confirming that the cancers 
arose independently [3, 6, 7].
DFT1 was first observed in 1996 and has triggered 
severe population declines across most of the island state 
of Tasmania [8, 9]. Extensive studies into the nature and 
biology of this tumour have identified DFT1 as a can-
cer of the Schwann cell lineage based on expression of 
transcription factors and proteins related to the myelina-
tion pathway [10]. Periaxin (PRX), a myelin protein, has 
proven to be a reliable diagnostic marker for DFT1 in 
tissue sections [10, 11]. Indeed, it was the lack of expres-
sion of PRX in collected DFTD samples that led to the 
discovery of DFT2 in southern Tasmania in 2014 [3]. As 
DFT2 was discovered only recently, its tissue-of-origin 
remains unknown, although it is known to express several 
markers consistent with a neuroectodermal origin [4]. An 
understanding of the founder cells of DFT2 tumours in 
devils will be paramount to further investigations into the 
susceptibility of this endangered species to transmissible 
cancers.
In this study, we compared the transcriptome and 
proteome of DFT2 tumours to DFT1 and normal Tas-
manian devil tissues to determine the tissue-of-origin of 
the DFT2 cancer. Our findings demonstrate that DFT2 
expresses a range of Schwann cell markers and exhibits 
expression patterns consistent with a similar origin to the 
DFT1 cancer. We discuss these findings in terms of cur-
rent knowledge of DFTD and propose a mechanism by 
which injury from biting behaviours may combine with 
other factors such as low genetic diversity to increase the 
risk of transmissible Schwann cell tumours emerging in 
the Tasmanian devil.
Materials and methods
Cell lines and biological samples
The DFT1 cell line C5065 was provided by A.-M. Pearse 
and K. Swift of the Tasmanian Department of Primary 
Industries, Parks, Water and Environment (DPIPWE). 
This cell line was previously established from a DFT1 
biopsy obtained under the approval of the Animal Ethics 
Committee of the Tasmanian Parks and Wildlife Service 
(Permit No. 33/2004-5, 32/2005-6). The DFT2 cell line 
SN and fibroblast cell line TD344 were established from 
single cell suspensions obtained from tissue biopsies. 
All cell cultures were maintained in RPMI 1640 medium 
(Thermo Fisher Scientific, Waltham, USA) supplemented 
with 10% foetal calf serum, at 35 °C and 5% CO2 in a 
humidified incubator. DFTD biopsies were collected from 
diseased devils using a 4 mm disposable biopsy punch 
(Kai Medical, Singen, Germany). Other primary tissue 
samples were obtained from Tasmanian devils ethically 
euthanised for welfare reasons. All samples were collected 
under the approval of the University of Tasmania Animal 
Ethics Committee (Permit Nos. A009215, A0012513 and 
A0014976).
RNA sequencing and analysis
Tissue samples stored in RNAlater (Thermo Fisher Scien-
tific, Waltham, USA) were homogenised for RNA extrac-
tion by bead-beating with 2.3 mm zirconia beads using 
a Mini-Beadbeater-24 (BioSpec Products, Bartlesville, 
USA). RNA was extracted using the  RNeasy® Mini Kit 
(QIAGEN Bioinformatics, Hilden, Germany), according to 
the instructions of the manufacturer. Duplicate biological 
replicates were prepared for each tissue type. Due to the 
minimal amount of peripheral nerve tissue that was avail-
able for this project, RNA samples were combined for this 
tissue to generate a RNA yield sufficient for sequencing. 
RNA integrity was assessed using a Eukaryotic RNA 6000 
Nano Kit and 2100 Bioanalyzer (Agilent, Santa Clara, 
USA). All samples had RIN scores greater than 9.0. 100 
base-pair single-read mRNA sequencing of duplicate sam-
ples for each tissue was performed on the Illumina Hiseq-
2500 platform (Illumina, San Diego, USA), as previously 
described [12]. Sequence quality was assessed using fastqc 
(http://www.bioin forma tics.babra ham.ac.uk/proje cts/
fastq c). Sequencing reads were aligned to the Tasmanian 
devil reference genome (7.0.82) using subread [13], and 
counts were summarized into genes using featureCounts 
[14]. Technical replicates were combined and a minimum 
threshold of 50 counts across all samples was applied to 
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exclude genes with extremely low expression. Expression 
levels were normalized by upper quartile normalisation 
using EDAseq [15]. Differential gene expression was cal-
culated using limma/voom (Online resource 1) [16]. Box-
plots of pairwise Euclidean distances of gene expression 
between DFT1 and DFT2, and between human tumours 
originating from the same and different tissue types were 
calculated using RPKM-normalised DFTD read counts 
and human cancer data obtained from Weinstein et al. 
[17]. The difference in the distribution of pairwise dis-
tances between the ‘within’ and ‘between’ tissues-of-
origin groups in human cancers was calculated using a 
Wilcoxon rank sum test. The difference in the distribu-
tion of pairwise distances between DFTD and the human 
‘within’ and ‘between’ tissue-of-origin groups was cal-
culated using a Kolmogorov–Smirnov test. Hierarchical 
clustering of sample data (columns) was performed on 
the union of differentially expressed genes (logFC > 2.0, 
p < 0.05) using the R package pvclust, according to the 
average method and a correlation-based dissimilarity 
matrix. Approximately unbiased p values (AU) and boot-
strap probabilities (BP) were estimated from 1000 boot-
strapping iterations. Genes (rows) were clustered based 
on Pearson’s correlation coefficient. Heat map colour rep-
resents the number of standard deviations each data point 
lies from the population mean across all tissue samples 
(z score). For functional enrichment analysis, enriched 
GO terms, KEGG pathways and REACTOME pathways 
were clustered into functionally-associated groups based 
on shared genes (kappa score > 0.4) using ClueGO ver-
sion 2.5 [24]. Single sample gene set enrichment analysis 
(ssGSEA) was performed using the GSVA R package, and 
gene set enrichment analysis (GSEA) was performed using 
GSEA 3.0 [18, 19]. Gene sets analysed using ssGSEA and 
GSEA were obtained from a previous study exploring the 
Schwann cell transcriptome during response to injury in a 
mouse model [20]. Enrichment of the top 50 up-regulated 
genes during injury was analysed in devil tissues to rep-
resent a repair Schwann cell phenotype, and the top 50 
down-regulated genes were analysed to represent a myeli-
nating Schwann cell phenotype.
Protein extraction and digestion
Triplicate samples of C5065, SN and TD344 cell lines were 
resuspended in 1 ml of 100 mM triethylammonium bicarbo-
nate (TEAB, Sigma Aldrich) containing 1% (w/v) sodium 
deoxycholate (SDC, Sigma Aldrich, pH7.8–8.2) and lysed 
at 95 °C for 5 min. Protein samples were incubated at room 
temperature with Benzonase nuclease (Sigma Aldrich) for 
30 min to degrade RNA and DNA. Protein was recovered by 
removing the supernatant after centrifugation (14,000g for 
5 min at 4 °C), and the protein concentration was estimated 
using a colorimetric bicinchoninic acid (BCA) protein assay 
kit (Pierce™). Protein (100 µg) from each biological sam-
ple was reduced at 65 °C for 30 min using dithiothreitol 
(DTT; 10 mM), then alkylated with iodoacetamide (IAA; 
20 mM) at room temperature for 30 min and digested with 
trypsin (5 µg) overnight at 37 °C. Samples were acidified 
with formic acid (1% v/v) to precipitate the sodium deoxy-
cholate. Sodium deoxycholate was removed by centrifuga-
tion (14,000×g for 5 min at 4 °C) and the peptide superna-
tant dried by vacuum concentration. Peptides were stored at 
− 20 °C and resuspended in 2% acetonitrile and 0.1% formic 
acid in water, before analysis by LC–MS.
High pH fractionation
For each cell line, 50 µg of protein from each of three repli-
cates was combined to generate a pooled sample (150 µg), 
which was purified using a Sep-Pak C18 column (Waters) 
as per the manufacturer’s guidelines. Peptides were eluted 
in two steps; 40% acetonitrile followed by 80% acetonitrile 
with 0.1% formic acid. Peptides from both elution steps were 
dried by vacuum centrifugation then resuspended in 5 mM 
ammonium hydroxide and combined before separating using 
a ZORBAX-300SB-C18 Extend column (2.1 × 150 mm, 
3.5 µm, 300 Å, Agilent) using an Agilent 1260 HPLC sys-
tem equipped with a fraction collector. Peptides were eluted 
using a linear gradient of 5 mM ammonium hydroxide in 
90% acetonitrile from 3 to 30% over 55 min, then 30–70% 
over 10 min at a flow rate of 0.3 ml/min. Fractions were 
collected every 1 min, combined into a total of 13 fractions 
for each cell line, then dried by vacuum centrifugation and 
resuspended in 2% acetonitrile with 0.1% formic acid for 
LC/MS analysis.
LC–MS/MS analysis and data acquisition
Nanoflow LC–MS/MS was carried out in positive mode 
using a Triple TOF 6600 mass spectrometer (SCIEX) 
equipped with an Eksigent nanoLC 400 liquid chroma-
tography system (SCIEX) and nanoflex cHiPLC module 
(SCIEX). Peptides (10 µl, approx. 2 µg) were desalted with 
2% acetonitrile (0.1% formic acid) at a flow rate of 5 µl/min 
for 5 min using a C18 trap (2 cm, 200 μm, 2.7 μm, Halo 
C18) for both Information Dependant Acquisition (IDA) and 
data independent (SWATH) experiments. For IDA, peptides 
were separated on a cHiPLC C18 column (15 cm × 200 μm, 
3 μm, ChromXP C18CL, 120 Å, 25 °C, SCIEX) using a 
linear solvent gradient from 2% acetonitrile (0.1% formic 
acid) to 35% mobile phase B (B: 90% acetonitrile, 0.1% for-
mic acid) at 600 nL/min over 120 min. For SWATH data 
was acquired using a 60 min LC gradient (5–35% mobile 
phase B) at 600 nl/min. Liquid chromatography eluent was 
subjected to positive ion nanoflow electrospray MS analysis 
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(spray voltage 2.5 kV, curtain gas 25, GS1 20) using a nano-
spray III source (SCIEX) and an uncoated PicoTip Emit-
ter (10 cm, 360 μm O.D., 20 μm I.D., New Objective). For 
spectral library generation in IDA mode, high pH fractions 
were analysed using a TOFMS survey scan (m/z 350–1500, 
200 ms) followed by MS/MS analysis (100 ms each, m/z 
100–1800) of the top 20 most intense precursor ions with an 
exclusion time of 30 s. For SWATH experiments, samples 
were analysed in data independent mode using m/z variable 
windows (100 in total) determined based on precursor m/z 
densities from IDA data. In SWATH mode a TOFMS sur-
vey scan was acquired (m/z 350–1500, 30 ms, high reso-
lution setting of 30,000) followed by 100 SWATH-MS2 
scans (m/z 350–1500, 30 ms, variable windows, high sen-
sitivity setting of 15,000). Each SWATH-MS2 scan used 
a rolling collision energy (CE = 0.06 × m/z − 1 for +2 ions 
and, CE = 0.06 × m/z − 3 for +3 to 5 ions) and CE spread 
of 5. SWATH experiments for each digested sample were 
Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus…
1 3
acquired in a random order with one blank injection acquired 
between each sample.
LC–MS/MS data analysis
Data was searched using the Paragon algorithm (SCIEX) in 
ProteinPilot (Version 5.0, SCIEX) in thorough ID mode with 
FDR calculation enabled and allowing biological modifica-
tion. MS/MS spectra from all IDA experiment were searched 
against a reference database for the Tasmanian Devil (Sar-
cophilus harrisii, UniProt KB, 22, 388 entries, November 
2016) to generate a spectral library. Carbamidomethyl modi-
fication of cysteine residues, and an Unused cut-off score 
of 1.3 (95% confidence) was used for database searches. 
For SWATH quantitation, ProteinPilot IDA search results 
for all high pH fractions were imported into PeakView2.1 
with SWATH2.0 MicroApp (SCIEX) and used as a spec-
tral library. Retention times for all Tasmanian devil facial 
tumour SWATH files were aligned using linear regression 
and by selecting five endogenous peptides across the elu-
tion profile. The top six most intense fragment ions for each 
peptide were extracted from the SWATH data using a maxi-
mum number of peptides of 100, 75 ppm mass tolerance, 
peptide confidence threshold of ≥ 0.99, and a 5 min retention 
time extraction window. After data processing, peptides with 
confidence ≥ 99% and FDR ≤ 1% (based on chromatographic 
feature after fragment extraction) were used for quantita-
tion. SWATH protein area data (summed area under the 
curve (AUC) values for each protein) were extracted using 
PeakView and compared across triplicate biological sam-
ples for DFT1, DFT2 and fibroblast cell lines. Protein peak 
areas were  log2 transformed and normalised by subtracting 
the total protein area for each sample. Two approaches were 
used to assess differentially expressed proteins including 
an analysis of variance (ANOVA) of the log-transformed 
normalised peak areas and a pairwise comparison using a 
two-sample Student’s t test adjusted for multiple compari-
sons by Benjamini–Hochberg correction (Online resource 
2) [21]. Proteins with p  < 0.05 (ANOVA) and an expression 
fold-change greater than ± 2.0 with FDR < 0.05 by t test were 
considered significantly altered between respective cell lines. 
Gene ontology analysis of significantly altered proteins was 
performed using DAVID version 6.8 [22, 23]. For analysis 
of highly expressed proteins in DFT2, enriched GO terms, 
KEGG pathways and REACTOME pathways were clustered 
into functionally-associated groups based on shared genes 
(kappa score > 0.4) using ClueGO version 2.5 [24]. For both 
analyses, protein lists were analysed using the Homo sapiens 
species database to overcome the paucity of biological data 
available for the Tasmanian devil.
Histology and immunohistochemistry
Tissue sections were fixed in 10% neutral buffered formalin 
and 3 µm paraffin sections were prepared and placed onto 
3-aminotriethoxysilane-coated slides for staining. Standard 
hematoxylin and eosin (H&E) staining and immunohisto-
chemical staining was performed as previously described 
[11]. The antibodies and dilutions used for immunohisto-
chemistry are given in Online resource 3.
Availability of data and materials
The datasets supporting the conclusions of this article are 
available in the European Nucleotide Archive repository 
[http://www.ebi.ac.uk/ena/data/view/PRJEB 28680 and 
http://www.ebi.ac.uk/ena/data/view/PRJNA 41637 8], and 
the ProteomeXchange Consortium via the PRIDE partner 
repository [http://www.ebi.ac.uk/pride /archi ve/proje cts/
PXD01 1209]. The remainder of the data supporting this 
article are included within the article and its additional files.
Results
Transcriptome analysis of DFT2 cell lines 
and primary tissues
DFT2 cancers are known to share a similar neuroectodermal 
origin to DFT1 [4], but a more precise understanding of 
the tissue-of-origin of DFT2 is required to understand their 
Fig. 1  Analysis of mRNA expression variation among DFT1 and 
DFT2 cell lines and primary tissues. a, b Gene expression was ana-
lysed in duplicate samples of DFT1 and DFT2 cell lines by RNA 
sequencing. a A continuous bar plot displaying the logFC of 12,632 
genes in DFT2 cell lines relative to DFT1 is shown. Genes are ranked 
along the x-axis from lowest logFC to highest logFC. Vertical dashed 
lines represent a fourfold difference in gene expression between the 
two tumours. b Boxplots of pairwise Euclidean distance between 
DFT1 and DFT2 cell lines and biopsies, and between human tumours 
originating from the same and different tissue types, are shown. 
Mean, interquartile range and outliers are indicated for each distri-
bution. Statistical significance is defined as n.s.p > 0.05, *p < 0.05, 
**p < 0.01, ***p < 0.001. c, d Gene expression was analysed in pri-
mary DFT1 and DFT2 tumour samples, testis, brain, spleen, heart 
and peripheral nerve by RNA sequencing. Two biological replicates 
were individually sequenced for each tissue type except for peripheral 
nerve (PN), where it was necessary to pool the two replicates prior to 
sequencing to generate sufficient template for analysis. c Hierarchi-
cal clustering of sample data (columns) was performed on the union 
of differentially expressed genes (logFC > 2.0, p < 0.05) and approxi-
mately unbiased p values (AU; coloured red) and bootstrap prob-
abilities (BP; coloured green) were estimated from 1000 bootstrap-
ping iterations using pvclust. Genes (rows) were clustered based on 
Pearson’s correlation coefficient. Heat map colour represents mean 
gene expression standardised across tissues (z score). d Mean pair-
wise distance between samples was calculated from log transformed 
RPKM-normalised mRNA read counts, based on Pearson’s correla-
tion coefficient. Each value represents the average of the two biologi-
cal replicates
◂
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emergence. To determine the tissue-of-origin of DFT2 cells, 
we first performed deep mRNA expression analyses of DFT1 
and DFT2 cell lines and primary tumour samples. Analy-
sis of the transcriptome of DFT1 and DFT2 cell lines via 
RNA sequencing revealed a total of 12,632 genes (Online 
resource 1), with 10,118 (80.1%) expressed at similar levels 
(fold change < ± 4.0) across the DFT1 and DFT2 cell lines 
(Fig. 1a). To determine whether this variation is consistent 
with a similar tissue-of-origin, we computed the pairwise 
distance in gene expression between DFT1 and DFT2 cell 
lines and compared this with the pairwise distance in gene 
expression between publicly-available human cancer data-
sets of the same tissue-type and of different tissue-types 
(Fig. 1b) [17]. As cell lines are susceptible to biological 
changes in culture, we also included primary DFT1 and 
DFT2 biopsies in this analysis. The variation in gene expres-
sion between DFT1 and DFT2 cell lines was significantly 
lower than variation between human cancers of different tis-
sue types (p = 0.006), but comparable to variation in human 
cancers within the same tissue type (p = 0.487) (Fig. 1b). In 
comparison, the variation between DFT1 and DFT2 biopsies 
was not significantly different to human cancers of the same 
(p = 0.973) or different (p = 0.263) tissue types. The increase 
in pairwise distance between DFT1 and DFT2 biopsies rela-
tive to cell lines could be attributable to the presence of 
immune infiltration in DFT2 biopsies [25]. Nonetheless, as 
the measured distance between DFT1 and DFT2 biopsies 
overlaps the distribution of pairwise distances among human 
cancers of the same tissue type (Online Resource 4), these 
data suggests that DFT1 and DFT2 could be of a similar 
origin.
To provide definitive evidence for a similar tissue-of-
origin of DFT1 and DFT2 cancers, we next compared gene 
expression patterns among primary DFT1 and DFT2 tumour 
biopsies and normal tissues from the Tasmanian devil, 
including testis, spleen, heart, brain and peripheral nerve 
(Online resource 1). Hierarchical clustering analysis of RNA 
sequencing data revealed that expression patterns in DFT2 
tumours were most similar to DFT1 and peripheral nerve, a 
Schwann cell enriched tissue (Fig. 1c). Pairwise distances 
calculated between each tissue also demonstrated lower vari-
ation amongst DFT1, DFT2 and peripheral nerve samples 
than any other tissue type (Fig. 1d). These findings suggest 
that, like DFT1, DFT2 cancers exhibit a gene expression 
profile that is similar to cells of Schwann cell origin.
Proteome analysis of DFT2 cell lines
Our transcriptomic analysis suggests that DFT2 cancers 
could have arisen from a similar cell of origin to DFT1. 
However, as protein levels can be regulated independently of 
mRNA, it was necessary to confirm these findings through 
analysis of DFT2 cells at the protein level. To examine 
the proteomic landscape of DFT2 tumours, we performed 
quantitative proteomics using the SWATH data independ-
ent acquisition (DIA) approach (Online resource 2). A pri-
mary Tasmanian devil fibroblast cell line was included in the 
analysis as a ‘healthy tissue’ reference line. To investigate 
the proteomic signatures of interest in DFT1 and DFT2 cells, 
we selected proteins that were expressed at least twofold 
higher in DFT1 or DFT2 cell lines relative to fibroblasts 
with FDR < 0.05. Gene ontology (GO) analysis using the 
proteomic database DAVID revealed significant enrichment 
of the GO term ‘myelin sheath’ in these DFT1 and DFT2 
protein sets (Fig. 2a–b; Online resource 5). The term ‘myelin 
sheath’ was also highly enriched when a subset of proteins 
that appeared in both of these DFT1 and DFT2 protein sets 
was analysed (Fig. 2c; Online resource 5). Conversely, anal-
ysis of highly expressed proteins in fibroblasts relative to 
DFT1 or DFT2 cells failed to reveal substantial enrichment 
of this term (Online resource 5). To further investigate this 
finding, we measured for enrichment of GO terms, KEGG 
pathways and REACTOME pathways among the 100 most 
highly expressed proteins in DFT2 cells relative to fibro-
blasts. Clustering of these terms into functionally organised 
networks using ClueGO revealed that 14.1% of enriched 
terms were associated with ‘neural crest cell development’, 
while 6.1% of terms were associated with ‘positive regula-
tion of myelin’ (Fig. 2d; Online resource 6). In comparison, 
other enriched terms represented basic structural and meta-
bolic functions of cells such as collagen trimerization and 
transferase activity. As Schwann cells develop from the neu-
ral crest and are responsible for the myelination of peripheral 
nerves, these findings reflect the transcriptome data and are 
consistent with a Schwann cell origin of DFT2 tumours.
Schwann cell marker expression in DFT1 and DFT2 
tumours
Schwann cells are a highly specialised cell type originat-
ing from the neural crest and functioning in myelination 
and maintenance of peripheral nerves. To reach a mature 
Schwann cell stage, neural crest cells undergo several dif-
ferentiation steps from a Schwann cell precursor, to an 
immature Schwann cell, and finally to a mature myelinat-
ing or non-myelinating Schwann cell [26]. To confirm that 
DFT2 arose from the Schwann cell lineage, we analysed 
specific markers of myelination and Schwann cell differ-
entiation in primary DFT tumours by mRNA sequencing 
and immunohistochemistry. At the mRNA level, important 
markers of Schwann cell differentiation, including SRY-
box 10 (SOX10) [27, 28], nerve growth factor receptor 
(NGFR) [29] and the neuroepithelial marker nestin (NES) 
[30], were highly expressed in DFT1 and DFT2 relative to 
testis, a control tissue selected for its expression of a broad 
range of genes (Fig. 3a). Markers of precursor Schwann 
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cells, such as growth-associated protein 43 (GAP43) and 
fatty acid-binding protein 7 (FABP7) [31, 32], were not 
highly expressed in either DFT1 or DFT2, suggesting that 
both tumours likely arose from a differentiated cell type. 
Analysis of genes required for myelination, including the key 
transcription factor early growth response 2 (EGR2) [33], 
and the structural myelin proteins PRX, myelin-associated 
glycoprotein (MAG) and myelin protein zero (MPZ) [34], 
revealed expression levels that were lower in DFT2 cells 
than peripheral nerve and DFT1 tissues, but higher than the 
testis control (Fig. 3a). This finding was supported by analy-
sis of Schwann cell markers at the protein level by immu-
nohistochemistry, which demonstrated lower expression of 
the myelin proteins PRX and peripheral myelin protein 22 
(PMP22) in DFT2 sections compared to DFT1 (Fig. 3b). 
Other Schwann cells markers were detected at various levels 
at the protein level across both DFT1 and DFT2 tissue sec-
tions (Fig. 3b; Online resource 7). Importantly, expression 
of all markers in the surrounding normal tissue of the section 
was either lower or absent, demonstrating the specificity of 
the markers to DFT1 and DFT2 cells. Moreover, high levels 
of the specific neural crest lineage marker SOX10 [27, 28] 
were detected at the protein level in both DFT1 and DFT2 
sections. Although SOX10 is expressed by other cell types 
arising from the neural crest including neurons, astrocytes, 
oligodendrocytes and melanocytes [27, 28], the absence of 
mRNA encoding markers of these other lineages in DFT1 
and DFT2 transcriptomes supports origins of these cells 
Fig. 2  Proteomic analysis of DFT1 and DFT2 cell lines. Protein 
expression was analysed in triplicate samples of DFT1, DFT2 and 
fibroblast cell lines by high throughput proteomic mass spectrom-
etry. Proteins expressed at least twofold higher in DFT1 or DFT2 cell 
lines relative to fibroblasts were selected for functional enrichment 
analysis. a–c Plots represent cellular component GO terms associ-
ated with proteins highly expressed relative to fibroblasts in a DFT1 
cells, b DFT2 cells and c both DFT1 and DFT2 cells, as determined 
by enrichment analysis using the proteomic database DAVID. Fold 
enrichment of up to ten terms significantly associated with each gene 
set is shown (p < 0.01). The Schwann cell associated term ‘myelin 
sheath’ is highlighted in each graph in dark blue. d The top 100 most 
highly expressed genes in DFT2 cells lines relative to fibroblasts 
were analysed by ClueGO. Enriched GO terms, KEGG pathways 
and REACTOME pathways were clustered into functionally-asso-
ciated groups (shown as different colours) by shared genes (kappa 
score > 0.4). Each group is labelled by the most significant term in the 
group. The size of each node represents it’s significance
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from the Schwann cell lineage (Online resource 8). Due to 
its strong expression in both DFT1 and DFT2 tumours and 
restricted expression in other cell types, SOX10 could poten-
tially be used in combination with the DFT1-only marker 
PRX [10, 11] to diagnose and distinguish DFT1 and DFT2.
Differential analysis of DFT1 and DFT2 tumours
Although both DFT1 and DFT2 cells are of Schwann cell 
origin, the suppression of myelin-specific genes in DFT2 
cells could indicate a difference in the pathways that con-
tribute to tumorigenesis in these cancers. To understand 
the differences between DFT1 and DFT2 tumours, we 
analysed for enrichment of GO terms, KEGG pathways 
and REACTOME pathways among the top 500 up-regu-
lated and down-regulated genes between DFT1 and DFT2 
cell lines. Clustering of these terms into functionally-
associated groups using ClueGO revealed that 78.26% of 
enriched terms in the DFT1 gene set were associated with 
‘channel activity’ (Fig. 4a; Online resource 9), a func-
tion thought to be important for communication between 
Schwann cells and nerve axons [35]. In comparison, 
enriched terms associated with the DFT2 gene set repre-
sented functions such as ‘anatomical structure morphogen-
esis’, ‘cell migration’ and ‘response to wounding’. These 
terms are consistent with known phenotypic changes that 
occur in Schwann cells during peripheral nerve injury, 
including suppression of myelination pathways, activa-
tion of wound repair responses and differentiation into 
invasive mesenchymal-like cells primed for nerve remod-
elling [36–38]. To further test if these repair pathways 
are implicated in DFT2 tumorigenesis, we performed an 
Fig. 3  Analysis of Schwann cell 
marker expression in DFT1 and 
DFT2 tumours. a Gene expres-
sion was analysed in peripheral 
nerve (PN), DFT1 and DFT2 
tumour samples and testis by 
RNA sequencing. Average 
RPKM-normalised read counts 
of Schwann cell lineage markers 
and myelination markers were 
plotted for each tissue. b Rep-
resentative tissue sections from 
DFT1 and DFT2 tumours were 
stained with H&E or antibodies 
against the Schwann cell mark-
ers PRX, SOX10, S100 (multi-
ple gene isoforms), NES, NGFR 
and PMP22. Serial sections 
were chosen to include tumour 
cells (indicated by an arrow-
head) and a peripheral nerve 
bundle (indicated by an arrow) 
as a Schwann cell enriched tis-
sue. Scale bars represent 50 µm
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unsupervised single sample gene set enrichment analy-
sis (ssGSEA) using gene sets previously shown to be 
up- or down-regulated in a mouse model of Schwann 
cell injury [20]. This analysis demonstrated increased 
enrichment of Schwann cell repair genes and decreased 
enrichment of genes associated with myelinating Schwann 
cells in DFT2 biopsies relative to other tissues (Fig. 4b; 
Online resource 10). In comparison, peripheral nerve tis-
sue exhibited enrichment of repair Schwann cell genes 
that was comparable to the brain control tissue, while 
DFT1 exhibited a phenotype that was intermediate to 
both DFT2 and PN. These findings were supported by 
GSEA analysis, which revealed significant enrichment 
of repair Schwann cell genes (normalised enrichment 
score = 1.71, FDR = 0.003), and negative enrichment of 
myelinating Schwann cell genes (normalised enrichment 
score = − 0.67, FDR < 0.001) in DFT2 biopsies relative to 
PN (Fig. 4c). In comparison, DFT1 biopsies exhibited only 
a marginal negative enrichment of myelinating Schwann 
cell genes relative to PN samples (normalised enrichment 
score = − 0.44, FDR = 0.034), and no significant enrich-
ment of repair Schwann cell genes (normalised enrich-
ment score = 0.42, FDR = 0.149). Given this evidence for 
enrichment of repair Schwann cell genes and functions in 
DFT2 cell lines and tumour biopsies, these pathways could 
be implicated in DFT2 tumorigenesis.
Fig. 4  Analysis of differentially expressed genes and functions among 
DFT1 and DFT2 tumours. a Gene expression was analysed in DFT1 
and DFT2 cell lines by RNA sequencing. The top 500 most highly 
expressed genes in DFT1 cell lines relative to DFT2, and DFT2 cell 
lines relative to DFT1, were analysed by ClueGO. Enriched GO 
terms, KEGG pathways and REACTOME pathways were clustered 
into functionally-associated groups (shown as different colours) by 
shared genes (kappa score > 0.4). Each segment of the pie chart rep-
resents the percentage of significantly-enriched terms (p < 0.001) that 
clustered with each group. Groups are labelled by their most signifi-
cant term. b Unsupervised enrichment analysis (ssGSEA) of gene 
sets differentially expressed during the Schwann cell (SC) repair 
response (as measured in a mouse model by Arthur-Farraj et  al. 
[20]) was performed across PN, DFT1, DFT2, brain and testis tis-
sues. An average enrichment score for the myelinating Schwann cell 
phenotype and the repair Schwann cell phenotype is plotted, with 
error bars representing the standard error of enrichment within each 
tissue-type across 50 specific genes. c Enrichment analysis (GSEA) 
of the above repair and myelinating gene sets was performed among 
DFT1 and DFT2 tissues relative to PN. Enrichment plots are shown 
for each comparison. The barcode plot indicates the position of genes 
rank-sorted according to differential expression, with over- and under-
expression represented by red and blue colouring. An enrichment 
score (ES), normalised enrichment score (NES) and false discovery 
rate (FDR) q value is given for each comparison
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Discussion
Given the rarity of transmissible cancers in mammalian 
species, the independent emergence of DFT1 and DFT2 
highlights a susceptibility of the Tasmanian devil to can-
cers of this nature. To further understand this phenom-
enon, we sought to identify the tissue-of-origin of the 
newly arisen DFT2 tumour using ‘omics-based approaches 
including RNA sequencing and quantitative proteomics. 
This approach incorporated the high sensitivity of RNA 
sequencing with the functionally informative nature of 
proteomic mass spectrometry to provide a comprehensive 
snapshot of the phenotype of the DFT2 cancer. The inte-
gration of these datasets revealed common patterns of gene 
and protein expression among both DFT1 and DFT2 cell 
lines and biopsies, demonstrating a Schwann cell origin of 
the two tumours. This finding suggests that the susceptibil-
ity of devils to transmissible cancer is cell-lineage specific, 
providing a basis for understanding the emergence of DFT 
cancers.
While many factors likely contributed to the develop-
ment of DFT1 and DFT2 in the Tasmanian devil, it has 
been hypothesised that disruption to the healing response 
within wounds could be a key factor in promoting Schwann 
cell oncogenesis in the devil [4]. Indeed, the innervated 
vibrissae on the facial regions of devils are vastly enriched 
with Schwann cells, and devils frequently obtain facial 
wounds from fighting and scavenging on sharp bone frag-
ments. Schwann cells are highly plastic and act as ‘guard-
ians’ of the peripheral nerve, undergoing a functional shift 
from myelin maintenance to myelin regeneration during 
wound repair [37]. Schwann cell plasticity during injury is 
controlled by Hippo signalling pathways [39], and involves 
regulation of a number of genes, including repression of 
myelin proteins [36, 37]. Strikingly, components of Hippo 
signalling pathways and downstream platelet-derived 
growth factor (PDGF) and ErbB2/ErbB3 pathways, have 
been implicated as key drivers of DFT1 and DFT2 tumo-
rigenesis in other studies [4, 40, 41]. Furthermore, our 
study demonstrates gene and protein expression profiles 
in DFT2 tumours that are consistent with activation of 
these repair pathways. These findings support a mecha-
nism by which the high frequency of facial injury and 
subsequent transition of Schwann cells to a repair pheno-
type in the Tasmanian devil may increase the likelihood 
of aberrations occurring in these cells, therefore giving 
rise to facial tumours on rare occasions. The potential 
for these Schwann cell cancers to become transmissible 
is perhaps increased in devils due to their unusual biting 
behaviors, which provide an uncontrolled route of tumour 
transfer [42]. Tissue injury and chronic inflammation are 
linked to a variety of cancer types in humans, and several 
inflammatory cytokines and growth factors released 
during wound healing can exert pro-oncogenic effects 
[43]. These factors include transforming growth factor β 
(TGFβ), a tumour-promoting cytokine expressed within 
DFT1 tumours [44] that acts as a key driver of Schwann 
cell repair in the wound environment [38]. Additionally, 
activation of repair pathways in DFTD cells could favour 
survival during cancer emergence. Indeed, the prolifera-
tive and invasive properties of mesenchymal-like repair 
Schwann cells [38] are likely to be indispensable for DFT2 
progression.
Although evidence suggests that Schwann cell plastic-
ity and injury could contribute to the specificity of DFT1 
and DFT2 to the Schwann cell lineage, there are likely to 
be additional factors that play a role to the emergence of 
these cancers in devils. A genetic susceptibility of devils 
to solid tumours is evident from historical post-mortem 
data from the San Diego Zoo, which reveals an incidence 
of non-DFTD cancer in captive devils that was at least two 
times higher than any other measured species and ten times 
higher than average [45, 46]. Furthermore, recent analysis 
has revealed that non-DFTD neoplasia is the most common 
cause of mortality in captive Tasmanian devils, responsible 
for approximately 40% of fatalities [47]. This predisposition 
of devils to cancer may be enhanced by low genetic diversity 
across the population due to historical population collapses 
induced by climate fluctuation and culling by early European 
settlers [4, 5, 48]. Low genetic diversity could also play a 
role in DFTD transmission by allowing transferred tumour 
cells to go unnoticed by the immune system. Indeed, DFT2 
tumours selectively express non-polymorphic major histo-
compatibility complex class I (MHCI) molecules that could 
be undetectable in genetically similar hosts [25]. Analysis of 
DFT1 cells suggests that tumour evolution and loss of this 
MHCI expression over time allows for the eventual transfer 
of the tumours into more diverse devil populations [25, 49].
The development of transmissible cancers in mammals 
is thought to be a rare event, occurring only when certain 
factors combine to overcome robust protective defences. 
Here we have reported that in the Tasmanian devil this 
has occurred not once, but twice, in founder cells from the 
Schwann cell lineage. While future studies will focus on the 
management of DFT1 and DFT2 in wild Tasmanian devil 
populations, the emergence of further DFTDs is also a pos-
sibility, and may increase the complexity of the conservation 
management of this iconic species. Further investigations 
into the remarkable development of DFTDs from Schwann 
cells in the devil will allow for identification of strategies to 
mitigate this risk.
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